Thrombosis, Cancer, and NOACs

Slides:



Advertisements
Similar presentations
Addressing the Challenges in Primary and Secondary Stroke Prevention
Advertisements

Covering the Bases in Cardioversion
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
NOACs for Cancer-Associated Thrombosis:
Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.
NOACs In Long-term VTE Treatment: A State Of The Art Review
Updates in Anticoagulation: What Did We Learn From ESC 2017?
Long-Term Treatment of VTE: Case Studies
US Guidelines US Guidelines Low-risk Patients.
Access to NOAC Therapy:
NOACs in Clinical Practice: Are They All the Same?
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
New Strategies to Prevent CV Events After Hospital Discharge
Emergency Management of NOAC Bleeding
A New Era for NOACs:.
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Anticoagulation Highlights From the American Heart Association Meeting 2017.
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
Oral Anticoagulants in AFa,b A Brief History.
Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
Stroke and AF.
New Oral Anticoagulants and VTE Management
VTE Treatment Conventional Approach
From Symptom Management to Communication in Advanced GI Cancers
AF and PCI in Practice.
Access to NOAC Therapy:
Antithrombotic Protection in CAD and HF
TAVR and the Risk of Thrombosis
Adherence in SPAF: Measures to Improve Care
Learning Objectives Classification of VTE Goals of VTE Treatment.
A Better Solution For Cancer Patients With VTE?
VTE in Cancer.
Reversal Strategies for VKA: Truths and Misconceptions
Real-World Evidence in VTE
Dos and Don’ts for High-Risk Elderly Patients With AF
Extending Treatment for Thrombosis: What’s the Right Choice?
Practical Considerations to Extend Treatment for VTE
Extraordinary Cases of VTE Prevention in Patients With Cancer
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Anticoagulation and Thrombosis Management
Aspirin and Cardioprevention in 2018
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Long-Term Treatment of VTE: Case Studies
Factor Xa Inhibitors in PAD
CAD/PAD in Primary Care
A Time for Change for Managing Patients With VTE Who Have Cancer
Cancer-Associated Thrombosis
Updates From the 2015 Meetings in Hemophilia
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Current Challenges in Managing Hemophilia
Updates in Anticoagulation: Key Sessions at ESC 2017
Managing Pulmonary Embolism Posthospital Discharge
NOAC Studies in VTE AF Studies Superior Outcomes.
Extraordinary Cases in VTE
How I treat cancer-associated venous thromboembolism
Program Goals Background: Anticoagulation in Patients With VTE.
Improving Adherence to Antiplatelet Therapy After an ACS Event
Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.
An Unmet Need.
Disease Burden of VTE Phases of VTE Treatment.
5 Good Minutes on Atrial Fibrillation-related Stroke
At the Crossroads of Coagulation
VKA Reversal and LVADs.
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Real-World Data in Cardiology: Focus on Atrial Fibrillation
Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.
Antithrombotic Therapy in AF Patients Undergoing PCI
What's New in NOACs in AF?.
Presentation transcript:

Thrombosis, Cancer, and NOACs

Program Goals

Cancer-Associated VTE

Oral Anticoagulants Are Preferred

Patient Persistence With Anticoagulation: LMWH vs Oral Agents

Hokusai VTE-Cancer Study: Design

Hokusai VTE-Cancer Study: Outcomes

Hokusai VTE-Cancer Study: Results

Hokusai VTE-Cancer Study: Results (cont)

Hokusai VTE-Cancer Study: Results (cont)

SELECT-D Trial: Design

SELECT-D Trial: Primary Endpoint

SELECT-D Trial: Results

Can Oral Anticoagulation Replace LMWH?

Patient Adherence

GI Bleeding

Patient Preferences

Treatment vs Prophylaxis

CASSINI Trial: Design

AVERT Trial: Design

Summary

Abbreviations